Trial · NCT07129772
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
NCT07129772, Phase 2, Not yet recruiting, The University of Hong Kong
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma. Trials, record NCT07129772. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07129772
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
- NCT number
- NCT07129772
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 53 participants, estimated
- Lead sponsor
- The University of Hong Kong
- Conditions
- Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
- Interventions
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- First posted
- 2025-08-19
- Last updated
- 2025-09-04
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response rate | 36 months | Rate of the absence of all detectable cancer cells in tissue samples examined under a microscope by certified pathologists after perioperative treatment with gemcitabine, cisplatin and pembrolizumab and minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) for locally recurrent nasopharyngeal carcinoma |
| Secondary | Objective response rate | 36 months | Rate of objective response as per RECIST 1.1 or irRECIST |
| Secondary | Major pathological response | 36 months | Rate of the less than or equal to 10% of detectable and viable cancer cells in tissue samples examined under a microscope by certified pathologists after perioperative treatment with gemcitabine, cisplatin and pembrolizumab and minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) for locally recurrent nasopharyngeal carcinoma |
| Secondary | Recurrence-free survival | 36 months | Rate of survival calculated from the time of the date of written informed consent to the date of radiologically confirmed recurrence of nasopharyngeal carcinoma or the date of death from any cause |
| Secondary | Overall survival | 36 months | Rate of survival calculated from the time of the date of written informed consent to the date of death from any cause |
| Secondary | Toxicity profiles | 36 months | Number of participants who suffer from adverse events or serious adverse events according to Common Terminology Criteria for Adverse Events version 5.0 |
| Secondary | Biomarkers | 36 months | Number of participants found to have biomarkers including tumor and blood biomarkers predictive of objective response to perioperative treatment with gemcitabine, cisplatin and pembrolizumab |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36535566 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07129772
GET https://conductscience.org/api/trials/v1/NCT07129772/registered